DEPARTMENT OF HEALTH

The Epidemiology of Tuberculosis in Minnesota 2018 – 2022

Minnesota Department of Health

Tuberculosis Prevention and Control Program

(651) 201-5414 | www.health.state.mn.us/tb


TB Morbidity and Mortality Minnesota, 2018-2022

as of September 29, 2023


| Year | No. of New Cases (Rate)* | No. of TB Deaths (% of New Cases)** |
|------|--------------------------|-------------------------------------|
| 2018 | 172 (3.1) | 2 (1) |
| 2019 | 148 (2.6) | 7 (5) |
| 2020 | 117 (2.1) | 6 (5) |
| 2021 | 134 (2.4) | 11 (8) |
| 2022 | 132 (2.3) | 8 (6) |

* Cases per 100,000 population. Rates calculated using state population estimates from the U.S. Census Bureau. ** Represents only deaths due to TB disease or TB drug-induced toxicity; percentages based on the number of new TB cases for each year


Active TB Cases Reported Annually Minnesota, 2003-2022




TB Incidence Rates per 100,000 Population United States and Minnesota, 2003-2022




2025 CDC TB Incidence Reduction Targets for US-born and Non-US-born populations, Minnesota, 2010-2022




2025 CDC TB Incidence Reduction Targets continued, Minnesota, 2014-2022



Proportion of TB Cases Born Outside of the United States United States and Minnesota, 2013-2022




TB Cases by Age Group and Place of Birth Minnesota, 2018-2022




*1 non-US-born case < 5 years old

TB Cases by Sex Assigned at Birth and Place of Birth Minnesota, 2018-2022




TB Disease by County of Residence Minnesota, 2022



| Location of Residence | Count (% of total) | | |
|---|--------------------|--|--|
| Hennepin County | 44 (33) | | |
| Ramsey County | 28 (21) | | |
| Suburban Metro* | 28 (21) | | |
| Greater MN | 32 (25) | | |
| Total | 132 | | |
| *Anoka, Carver, Dakota, Scott, Washington | | | |

TB Disease by County of Residence Minnesota, 2018-2022



| Location of Residence | Count (% of total) | | |
|---|--------------------|--|--|
| Hennepin County | 227 (32) | | |
| Ramsey County | 162 (23) | | |
| Suburban Metro* | 137 (19) | | |
| Greater MN | 177 (25) | | |
| Total 703 | | | |
| *Anoka, Carver, Dakota, Scott, Washington | | | |


Number of Cases and Incidence of TB by Location of Residence Minnesota, 2018-2022

| Location of Residence | 2018 No. (Rate)* | 2019 No. (Rate)* | 2020 No. (Rate)* | 2021 No. (Rate)* | 2022 No. (Rate)* |
|--|---------------------|---------------------|---------------------|---------------------|---------------------|
| Hennepin County | 54 (4.3) | 53 (4.2) | 44 (3.5) | 32 (2.5) | 44 (3.5) |
| Ramsey County | 34 (6.2) | 29 (5.3) | 31 (5.6) | 40 (7.3) | 28 (5.1) |
| Suburban Twin Cities Metro† | 33 (2.6) | 26 (2.0) | 20 (1.5) | 30 (2.3) | 28 (2.1) |
| Olmsted County | 12 (7.7) | 6 (3.8) | 1 (0.6) | 4 (2.5) | 5 (3.1) |
| Greater Minnesota (excluding Olmsted) | 39 (1.7) | 34 (1.4) | 21 (0.9) | 28 (1.2) | 27 (1.1) |
| Total | 172 (3.1) | 148 (2.6) | 117 (2.1) | 134 (2.4) | 132 (2.3) |

* Cases per 100,000 population. Rates calculated using state population estimates from the U.S. Census Bureau.

⁺ Anoka, Carver, Dakota, Scott, and Washington counties

TB Incidence Rate by Race*/Ethnicity Minnesota, 2018-2022




*Race categories do not include persons of Hispanic/Latino ethnicity. 1 multi-racial case is not included.

**Rate per 100,000 population. Calculated using population estimates from the U.S. Census Bureau.

TB Cases by Race/Ethnicity and Place of Birth Minnesota, 2018-2022


| Race* / Ethnicity | Non-US-Born Cases No. (%) | US-Born Cases No. (%) | | |
|--|------------------------------|--------------------------|--|--|
| White | 9 (2) | 40 (34) | | |
| Black/African-American | 298 (51) | 31 (26) | | |
| Asian | 225 (38) | 30 (25) | | |
| American Indian / Alaska Native | 0 | 4 (3) | | |
| Native Hawaiian / Pacific Islander | 3 (<1) | 1 (1) | | |
| Multi-racial | 0 | 1 (1) | | |
| Hispanic / Latine | 50 (9) | 11 (9) | | |
| Total | 585 (100) | 118 (100) | | |
| *Race categories do not include persons of Hispanic/Latine ethnicity | | | | |

Non-US-Born TB Cases by Visa Status Upon Arrival in the US Minnesota, 2018-2022




* "Other" includes visitors, tourists, students, and those arriving on employment visas

Non-US-Born TB Cases by Interval Between Arrival in US and Diagnosis of TB Minnesota, 2018-2022



TB Class Notifications* Among Refugees/Immigrants Diagnosed with TB within One Year After Arrival to US Minnesota, 2018-2022




* Per results of pre-immigration screening performed overseas

Non-US-Born TB Cases by Top Five Countries of Birth Minnesota, 2018-2022

| Country of Birth | No. of Cases (%) | |
|---|------------------|--|
| Somalia | 133 (23) | |
| Ethiopia | 71 (12) | |
| Laos | 53 (9) | |
| Viet Nam* | 32 (5) | |
| India* | 29 (5) | |
| Kenya | 29 (5) | |
| Other | 238 (41) | |
| Total | 585 | |
| * Top E participally in 2022 In order these countries | | |

* Top 5 nationally in 2022. In order, these countries are Mexico, Philippines, India, Viet Nam, China.


Number of TB Cases by Country of Birth Minnesota, 2018-2022



TB Cases by Method of Case Identification Minnesota, 2018-2022

| Method of Identification | No. of Cases (%) |
|--|------------------|
| TB symptoms | 580 (83) |
| TB contact investigations | 48 (7) |
| Overseas TB Class follow-up | 7 (1) |
| Domestic refugee health exam | 5 (<1) |
| Other immigration exams | 6 (<1) |
| Employment screening (including health care personnel) | 14 (2) |
| Other targeted testing | 16 (2) |
| Incidental imaging or lab result | 27 (4) |
| Total | 703 |

TB Cases by Risk Category* and Place of Birth Minnesota, 2018-2022



■ Non-US-Born ■ US-born

*Risk categories are not mutually exclusive

**Conditions or therapies increasing risk for progression to active TB disease, not including HIV/AIDS

⁺Excess alcohol use and/or injection or non-injection drug use

TB Cases With Other Medical Risk Factors* by Type of Risk Factor Minnesota, 2018-2022


| Medical risk factor** | Cases (N=703) No. (%) |
|--|--------------------------|
| Diabetes | 127 (18) |
| Immunosuppressive condition (not HIV/AIDS) or therapy*** | 55 (8) |
| End stage renal disease | 18 (3) |
| Weight loss/undernutrition/malabsorption | 18 (3) |
| Other (e.g. chronic kidney disease, active smoking, hematologic disease, COVID-19) | 171 (24) |
| * Conditions or therapies that increase risk for progression from latent TB infection to active TI | B disease, not including |

* Conditions or therapies that increase risk for progression from latent TB infection to active TB disease, not including HIV/AIDS

** Patients could have > 1 medical condition

*** Includes TNF α antagonist therapy and post-organ transplant anti-rejection drugs

HIV Testing in Persons with TB Minnesota, 2013-2022




■No. of eligible cases* -•-Percent of eligible cases with HIV result

*Alive at time of diagnosis

TB Cases by HIV Status and Place of Birth Minnesota, 2018-2022


| HIV Status | Non-US-Born Cases No. (%) | US-Born Cases No. (%) | Total No. (%) |
|---------------------|------------------------------|--------------------------|------------------|
| Negative | 557 (95) | 113 (96) | 670 (95) |
| Positive | 15 (3) | 1 (<1) | 16 (2) |
| Not Offered | 9 (2) | 2 (2) | 11 (2) |
| Refused HIV testing | 4 (<1) | 1 (<1) | 3 (<1) |
| Unknown | 0 | 1 (<1) | 1 (<1) |
| Total | 585 | 118 | 703 |

TB-HIV Co-infected Cases United States and Minnesota, 2013-2022



TB Cases by Site of Disease Minnesota, 2018-2022


N = 702



| Top five extrapulmonary sites of disease* | Cases (N=326)** No. (%) |
|--|----------------------------|
| Lymphatic | 153 (47) |
| Musculoskeletal | 57 (17) |
| Pleural | 45 (14) |
| Peritoneal | 36 (11) |
| Genitourinary | 23 (7) |

* Patients may have multiple extrapulmonary sites of disease
** Includes TB cases with and without concurrent pulmonary disease


TB Cases by Site of Disease and Place of Birth Minnesota, 2018-2022



* Includes cases with and without concurrent pulmonary disease


TB Cases by Case Verification Criteria* Minnesota, 2018-2022

N = 703




*Based on the public health surveillance definition for TB [CDC. (August 2021) CDC Tuberculosis Surveillance Data Training: 2020 Report of Verified Case of Tuberculosis (RVCT) Instruction Manual. Atlanta, GA: U.S. Department of Health and Human Services, CDC. (Appendix A - Tuberculosis Case Definition for Public Health Surveillance)]

TB Cases by Mycobacterial Culture Result Minnesota, 2018-2022




*No growth or growth of other Mycobacterium species not part of *M.tb* complex

TB Cases with Pulmonary Involvement by Initial Sputum AFB Smear Result Minnesota, 2018-2022



*50% of pulmonary cases without sputum smear results were under 15 years of age

TB Cases with Pulmonary Involvement by Chest Imaging* Result Minnesota, 2018-2022



* From initial chest x-ray or chest CT scan. Two cases with pulmonary involvement did not have chest imaging performing (1 diagnosis made post-mortem).

TB Cases by Drug Susceptibility Patterns and Year Minnesota, 2018-2022

| Year | Cases With Susceptibility Results* | Any Drug Resistance† No. (%) | INH- Resistant** No. (%) | MDR TB‡ No. (%) |
|-------|---------------------------------------|------------------------------------|--------------------------------|--------------------|
| 2018 | 134 | 26 (19) | 16 (12) | 7 (5) |
| 2019 | 126 | 17 (13) | 13 (10) | 6 (5) |
| 2020 | 90 | 12 (13) | 11 (12) | 3 (3) |
| 2021 | 94 | 10 (11) | 9 (10) | 4 (4) |
| 2022 | 103 | 13 (13) | 11 (11) | 3 (3) |
| Total | 547 | 78 (14) | 60 (11) | 23 (4) |

* Culture-confirmed cases with drug susceptibility results available


+ Resistance to at least one first-line anti-TB drug [i.e., isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), or ethambutol (EMB)]

** INH-resistant cases may also be resistant to other drugs

‡ Multi-drug resistant TB, defined as resistance to at least INH and rifampin (may also be resistant to other drugs)

Multi-drug Resistant TB (MDR TB) Minnesota, 2018-2022

Presumed, acquired, or non-countable MDR TB cases (burden cases)
Initial culture-confirmed MDR TB cases (surveillance cases)



TB Cases by Drug Susceptibility Patterns and Place of Birth Minnesota, 2018–2022

| Place of birth | Cases With Susceptibility Results* | Any Drug Resistance† No. (%) | INH- Resistant** No. (%) | MDR-TB‡ No. (%) |
|----------------|--|------------------------------------|--------------------------------|--------------------|
| Non-US-Born | 467 | 69 (15) | 53 (11) | 19 (4) |
| US-Born | 80 | 9 (11) | 7 (9) | 4 (5) |
| Total | 547 | 78 (14) | 60 (11) | 23 (4) |

* Culture-confirmed cases with drug susceptibility results available


⁺ Resistance to at least one first-line anti-TB drug [i.e., isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), or ethambutol (EMB)]

** INH-resistant cases may also be resistant to other drugs

[‡] Multi-drug resistant TB, defined as resistance to at least INH and rifampin

TB Cases by Type(s) of Provider* Minnesota, 2018-2022

Public health Z Both public and private/other Private/other



* Some patients are managed by multiple providers throughout disease course

TB Cases by Mode of Treatment Administration Minnesota, 2018-2022

| Year | Started treatment | At least some DOT* | Completely self-administered |
|-------|-------------------|--------------------|-------------------------------------|
| 2018 | 170 | 98% | 1% |
| 2019 | 146 | 100% | 0% |
| 2020 | 115 | 99% | <1% |
| 2021 | 129 | 99% | <1% |
| 2022 | 130 | 99%** | 0% |
| Total | 690 | 99% | <1% |

| Type of Provider | Started treatment | At least some DOT* | Completely self-administered | | | | |
|--|-------------------|--------------------|-------------------------------------|--|--|--|--|
| Public 397 | | 100% | 0% | | | | |
| Private only | 293 | 99% | 1% | | | | |
| *DOT = Directly Observed Therapy | | | | | | | |
| **Treatment administration unknown for 1 case. | | | | | | | |

Treatment Completion and Length of Therapy Among TB Cases Minnesota, 2017-2021 as of February 16, 2024

| Year | Started Treatment* | Completed Within 12 mos.** No. (%) | Completed Overall** No. (%) |
|-------|--------------------|--|-----------------------------------|
| 2017 | 138 | 132 (96) | 138 (100) |
| 2018 | 139 | 128 (92) | 135 (97) |
| 2019 | 114 | 102 (89) | 110 (96) |
| 2020 | 93 | 85 (91) | 92 (99) |
| 2021 | 102 | 90 (88) | 96 (94) |
| Total | 586 | 537 (92) | 571 (97) |

* Patients for whom < 12 months of therapy is indicated. This excludes patients with rifampin resistance, meningeal TB, TB in bone or skeletal system, TB in CNS, children 14 years of age or younger with disseminated TB, patients who died or moved out of US within 366 days of starting treatment.

** Treatment completion data as of 8/29/2022